Genomic Testing for Type 2 Diabetes Risk: A Prototype for Personalized Preventive Medicine?

24
Genomic Testing for Type 2 Diabetes Risk: A Prototype for Personalized Preventive Medicine? Alex Cho MD, MBA; Scott Joy MD; Julianne O’Daniel MS, CGC; Ley Killeya-Jones, PhD; Susanne Haga PhD; Isaac Lipkus PhD; Geoff Ginsburg MD, PHD Center for Genomic Medicine (IGSP) Duke University

description

Genomic Testing for Type 2 Diabetes Risk: A Prototype for Personalized Preventive Medicine?. Alex Cho MD, MBA; Scott Joy MD; Julianne O’Daniel MS, CGC; Ley Killeya-Jones, PhD; Susanne Haga PhD; Isaac Lipkus PhD; Geoff Ginsburg MD, PHD Center for Genomic Medicine (IGSP) Duke University. - PowerPoint PPT Presentation

Transcript of Genomic Testing for Type 2 Diabetes Risk: A Prototype for Personalized Preventive Medicine?

Page 1: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Genomic Testing for Type 2 Diabetes Risk: A Prototype for Personalized Preventive Medicine?

Alex Cho MD, MBA; Scott Joy MD; Julianne O’Daniel MS, CGC; Ley Killeya-Jones, PhD; Susanne Haga PhD; Isaac Lipkus PhD; Geoff Ginsburg MD, PHD

Center for Genomic Medicine (IGSP)

Duke University

Page 2: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Clinical Vignette

40 yo M, BMI <30, no FH

DM, not from higher-risk

group; wants screening for

diabetes

Page 3: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Genomics, Direct-to-Consumer

Page 4: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Why Prevention?

• Genomic discovery finding new associations with disease risk• Genomics can deliver what prevention requires

– Conditions w/ significant burden of suffering– Conditions w/ suitable natural history– Acceptable screening procedures– Treatments that work better early than late– Benefits outweigh harms– Benefits come at reasonable cost

• Genomics thus a potentially powerful tool to help rationalize imprecise practice

Page 5: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

At Reasonable Cost?

• Multiplex technologies have built-in economies of scale– $1,000 for 1,000,000 SNPs ~ 0.1¢ per SNP; no expiration

date• even on a per-condition basis, price is reasonable

– vs. CT scan of the head for HA = $425, good for 12h?• variant on 9p21 assoc w/ incr risk of intracranial

aneurysm (OR = 1.3); price = $195, includes VTE, AF too

• Cost issue is as much about the orientation of our healthcare system as it is about the actual cost of these technologies

Page 6: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Why Diabetes?

• Huge burden• Onset can be delayed, even prevented• Knowledge isn’t enough, but can be motivating• Current screening practice imprecise

– FPG most common; will be replaced by Hgb A1c– USPSTF recs screening only those w/ HTN, chol; ADA recs

screening more broadly– NHANES III found FPG alone misclassifies 20% of patients w/

diabetes, prediabetes as being nondiabetic – Oral glucose tolerance testing (OGTT) is “gold standard,” but more

expensive and less convenient• Clinical inertia around borderline results• Well-studied markers (~20 SNPs), GWA studies • Even an RCT showing benefit (DPP)

Page 7: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

TCF7L2

• TCF7L2 encodes for entero-endocrine transcription factor

• Role in Wnt signaling pathway

• Regulates peptide hormone made by enteroendocrine cells (glucagon-like peptide 1)

Page 8: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

TCF7L2 & Diabetes Prevention Program

Diabetes Prevention Program (DPP) not only showed association with risk of progression, but also that intervention reduces risk for higher-risk genotypes.

Source: Florez et al. N Engl J Med 2006;355:241-50.

Page 9: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

TCF7L2 & Diabetes Prevention Program

Source: Florez et al. N Engl J Med 2006;355:241-50.

Page 10: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Potential impact on patient behavior?

• We know that knowing is not enough• Adherence to lifestyle changes proven to reduce risk for T2DM

poor• Family history motivating for some

– e.g., study of 1100 African Americans found those aware of +FH T2DM were more likely to make healthier food choices

• REVEAL study– finding of ApoE4+ led to increased AD-specific behavior change

• Survey of patients and physicians re: their enthusiasm for the use of genetic information for T2DM risk– 71% of patients said this information would be motivating– 23% of providers said it would

Source: Baptiste-Roberts et al. 2007; Chao et al. 2008; Florez et al. 2009

Page 11: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Issue #1: What does this add to what we already know?

• Recent studies suggest the addition of genomic testing to standard risk assessment adds little to risk prediction– Meigs et al. and Lyssenko et al. found that the contribution of

specific genetic information only slightly improved upon the ability of a constellation of other clinical factors to predict who would progress to T2D.

– These factors included systolic blood pressure, high-density lipoprotein levels, and triglycerides in the former; and diastolic blood pressure, triglycerides, liver enzymes in the latter.

– However, Lyssenko et al. also pointed out that the risk prediction model from Meigs et al. performed worse than one based on genomic risk alone.

Source: Meigs et al. N Engl J Med 2008; Lyssenko et al. N Engl J Med 2008.

Page 12: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Issue #2: What if it “contradicts” what we already know?

Page 13: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Issue #3: What happens when risk estimates change?

Source: http://exploringmygenes.blogspot.com

Page 14: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

A Three-Part Approach

• Identify markers (i.e., SNPs)– Systematic review (TCF7L2, PPARg2, KCNJ11)– deCODE T2D (TCF7L2, PPARg2, CDKAL1, CDKNA2A/B)

• Build a clinical prototype– Duke Executive Health module– Other Duke clinics (e.g., Pickett)

• Build a research program– ‘Clinical utility’ RCT pilot– CHSRPC (Durham VAMC) study– Multiplex pilot??

Page 15: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

deCODE T2TM test for T2DM risk in 1 care

• Panel of 4 SNPs associated w/ increased risk of developing T2DM

• Retails for $300• Analyzed in a CLIA-certified lab• Can only be ordered by physician

Source: deCODE genetics.

Page 16: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

T2DM Genomic Risk Pilot Study

Glucose, Chem-7, or CMP is ordered by provider. Approach patient while waiting to have blood drawn. Verify fasting. Enroll on the spot (adding on insulin to lab draw)

‘Want genomic testing?’‘Yes’; randomize to receiving results up front vs. not. ‘No’; follow those who decline separately.

Inform pt of genomic test results.Counsel based on genomic, conventional risk factors.

Follow

Survey; measurest = 0

Survey; measurest = +12mo

Follow

Decline testing.Same as ‘Do not test’ arm. Assess reasons for declining.

Survey t = +3mo Survey; measurest = +12mo

Follow

Survey; measurest = +12mo

Follow

Do not inform pt of genomic test results.Counsel based on FH, BMI, FPG results alone.

RSurvey t = +3mo

Survey t = +3moSurvey t = after risk counseling

All subjects get testing w/ deCODE four-marker panel for T2DM risk

Follow

Follow

Page 17: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Risk Profile

Page 18: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Role for DNA testing in DM risk assessment?

40 yo M, BMI <30, no FH

DM, not from higher-risk

group; wants screening for

diabetes

‘elevated’ risk

baseline risk

annual OGTT (or Hgb A1c) screening + stepped-up

lifestyle change

screening w/ FPG every 3y if

physically inactive, 45,

chol, HTN + usual lifestyle

recs

prediabetic?

initiate early treatment w/ metformin

urge lifestyle change, consider early treatment w/

metformin

OGTT = oral glucose tolerance testing, FPG = fasting plasma glucose

Page 19: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Acknowledgements

• Study Team– Ley Killeya-Jones– Marylou Bembe– Dana Baker– Michael Scott– Sarah McBane– Gloria Trujillo

• The Duke Endowment• deCODE genetics

Page 20: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Resources

• National Human Genome Research Institute (NIH)– www.genome.gov

• National Office of Public Health Genomics (CDC)– HuGE Net

• Nat’l Coalition for Health Professional Education in Genetics (NCHPEG)

• Gene Tests (www.genetests.org)• Online Mendelian Inheritance in Man (OMIM)• HapMap (www.hapmap.org/whatishapmap.html)• Wellcome Trust (genome.wellcome.ac.uk)• Guilford County Genomedical Connection

(http://www.aheconnect.com/genomic_medicine) • Duke IGSP (www.genome.duke.edu)

Page 21: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Thank You

Page 22: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?
Page 23: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Additional Slides

Page 24: Genomic Testing for Type 2 Diabetes Risk:  A Prototype for Personalized Preventive Medicine?

Genomics, Direct-to-Consumer